More than 50% of patients are already enrolled in a phase III study

The study aims to evaluate the efficacy, safety and individual tolerance of treatment with a drug in patients with seborrheic dermatitis of the scalp.

This is a multicenter, randomized, blind, parallel-group phase III study.

Currently the number of screened patients comprises more than 50% of the total planned number of patients. Moreover, the number of randomized patients comprises 71%. The planned duration of treatment will total 4 weeks and the subsequent patient monitoring about two weeks.